Docoh
Loading...

CORT Corcept Therapeutics

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
On May 26, 2021, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect eight directors to hold office until our 2022 annual meeting of stockholders, and 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.

A total of 116,627,692 shares of Corcept Therapeutics Incorporated common stock held by stockholders of record at the close of business on April 16, 2021 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 102,368,830. The voting on the two matters is set forth below:

Proposal 1 — Election of Directors. The following directors were elected to serve until our 2022 annual meeting of stockholders.

DirectorForWithheldBroker Non-Votes
Gregg Alton80,997,8501,920,36919,450,611
G. Leonard Baker, Jr.80,662,8992,255,32019,450,611
Joseph K. Belanoff, M.D.82,359,986558,23319,450,611
Gillian M. Cannon, Ph.D.82,685,412232,80719,450,611
David L. Mahoney80,900,1142,018,10519,450,611
Kimberly Park80,498,9642,419,25519,450,611
Daniel N. Swisher, Jr.68,845,81714,072,40219,450,611
James N. Wilson80,794,1752,124,04419,450,611


Proposal 2 — To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.

For101,275,555
Against1,059,617
Abstain33,658
Broker Non-VotesN/A